Regeneron Pharmaceuticals Inc. faced a notable decline in its stock price as investor sentiment shifted amidst broader market concerns.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) experienced a drop of 1.27% in its stock price today, closing at CA$753.10. This decline reflects ongoing challenges in the biotech sector, which is grappling with market volatility and investor caution.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$76.86B
P/E
18.5x
Div. yield
0.49%
Div. / share
$3.64
52W high
$859.34
52W low
$561.12
1W change
+5.00%
Beta
0.15
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 12, 2026
Wall Street analysts forecast REGN stock price to rise 12.6% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$859.04
+12.6% Upside
Previously C$856.23 on Oct 9, 2026
Current Price
C$762.81
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.8%
Annualized
90-Day Vol
29.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$911.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$809.59 | C$733.03 – C$894.15 |
| 60 trading days | C$859.25 | C$746.63 – C$988.86 |
| 90 trading days | C$911.95 | C$767.79 – C$1083.17 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain vigilant as Regeneron navigates a challenging landscape, particularly in light of recent sector-wide sell-offs and the company's reliance on upcoming trial results and potential M&A activity.
1.27% Decline
Regeneron's stock has fallen by 1.27%, reflecting broader market concerns affecting the biotech sector.
Bull case
Despite today’s decline, Regeneron still has a promising outlook thanks to its innovative drug pipeline. The recent positive results for Pasatru, a treatment for fibrodysplasia ossificans progressiva, could support future growth.
Bear case
The biotech sector is under pressure, and Regeneron may continue to face challenges if market sentiment stays negative. Concerns about valuation and the potential for disappointing earnings in the upcoming report could weigh on the stock.
Market Context
Advertisement
The decline in Regeneron's stock price is part of a broader trend affecting biotech stocks, which have struggled to maintain their August highs. Experts suggest that while a wave of mergers and acquisitions could provide future catalysts, current investor sentiment remains cautious.
Recent Developments
Regeneron recently announced positive results for Pasatru, which showed sustained efficacy in clinical trials. However, the market's reaction has been muted, reflecting a general apprehension towards biotech valuations amid economic uncertainties.
Looking Ahead
As investors await Regeneron's upcoming earnings report, the focus will be on the company's ability to sustain its earnings surprise streak. The stock's performance may hinge on market conditions and the reception of its trial results, which could either bolster or further challenge investor confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
